A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

Osimertinib contributes to the higher efficacy and few intestinal side effects in non-small cell lung cancer (NSCLC) patients with T790M mutation. Previous studies has reported that intestinal microbiota play important roles in drug efficacy and toxicity. However, we have known less about the change...

Descripción completa

Detalles Bibliográficos
Autores principales: Cong, Jing, Zhang, Yuguang, Xue, Yadong, Zhang, Chuantao, Xu, Mingjin, Liu, Dong, Zhang, Ruiyan, Zhu, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683577/
https://www.ncbi.nlm.nih.gov/pubmed/33240237
http://dx.doi.org/10.3389/fmicb.2020.583525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683577/
https://www.ncbi.nlm.nih.gov/pubmed/33240237
http://dx.doi.org/10.3389/fmicb.2020.583525

Ejemplares similares